News

Clariant focuses on core products

28/04/2006

Swiss specialty chemical company Clariant has sold its Pharmaceutical Fine Chemicals unit to TowerBrook Capital Partners, L.P. for a transaction value of approximately CHF110 million ($87.6 million). The sale marks a further step in Clariant's strategy to focus its portfolio on core activities including textile and leather chemicals, and pigments and additives.

To continue reading this story, please sign in or register.

Leatherbiz.com cannot be held responsible for content if the language setting is changed from English.

The translations provided by Google Translate are automated and therefore might not be accurate and may contain incorrect, offensive or misleading language. We offer this facility as a guide only.